Abstract:
Acute pancreatitis (AP) is a commonly occurring gastrointestinal disorder. An increase in the annual incidence of AP has been observed, and it causes acute hospitalization and high mortality. The diagnosis and treatment guidelines for AP recommend conservative medical treatments focused on reducing pancreatic secretion and secondary injury, as a primary therapeutic approach. Unfortunately, the existing treatment options have limited impact on the incidence and severity of AP due to the complex and multifaceted pathological process of this disease. In recent decades, Chinese herbal medicines (CHMs) have been used as efficient therapeutic agents to attenuate AP in Asian countries. Despite early cell culture, animal models, and clinical trials, CHMs are capable of interacting with numerous molecular targets participating in the pathogenesis of AP; however, comprehensive, up-to-date communication in this field is not yet available. This review focuses on the pharmacological activities of CHMs against AP in vitro and in vivo and the underlying mechanisms. A computational prediction of few selected and promising plant-derived molecules (emodin, baicalin, resveratrol, curcumin, ligustrazine, and honokiol) to target numerous proteins or networks involved in AP was initially established based on a network pharmacology simulation. Moreover, we also summarized some potential toxic natural products for pancreas in order to more safe and reasonable medication. These breakthrough findings may have important implications for innovative drug research and the future development of treatments for AP.
摘要:
急性胰腺炎(AP)是一种常见的胃肠道疾病。已观察到AP的年发病率增加,导致急性住院和高死亡率。AP的诊断和治疗指南推荐以减少胰腺分泌和继发性损伤为重点的保守药物治疗。作为主要的治疗方法。不幸的是,现有的治疗方案对AP的发病率和严重程度的影响有限,这是由于AP的病理过程复杂和多方面.近几十年来,在亚洲国家,中草药(CHMs)已被用作减轻AP的有效治疗剂。尽管早期细胞培养,动物模型,和临床试验,CHMs能够与许多参与AP发病机制的分子靶标相互作用;然而,全面,该领域的最新通信尚不可用。本文综述了CHMs在体外和体内抗AP的药理活性及其潜在机制。对少数选定和有前途的植物衍生分子(大黄素,黄芩苷,白藜芦醇,姜黄素,川芎嗪,和和厚朴酚)靶向AP中涉及的许多蛋白质或网络最初是基于网络药理学模拟而建立的。此外,我们还总结了一些潜在的胰腺毒性天然产物,以便更安全合理的用药。这些突破性发现可能对创新药物研究和AP治疗的未来发展具有重要意义。